Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 1.6 %

Shares of LPCN opened at $3.12 on Tuesday. The stock has a market cap of $16.69 million, a PE ratio of -4.11 and a beta of 1.51. Lipocine has a 52-week low of $2.75 and a 52-week high of $11.79. The firm’s fifty day moving average is $3.31 and its two-hundred day moving average is $4.38.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its holdings in Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.